Second Sight Medical Products, Inc. (NASDAQ:EYES) reached 0.26% versus a 1-year low price of $1.32. The stock was last seen -14.62% lower, reaching at $1.32 on Mar. 10, 2017. At recent session, the prices were hovering between $1.32 and $1.44. This company shares are 1112.12% off its target price of $16 and the current market capitalization stands at $65.3M. The recent change has given its price a -24.07% deficit over SMA 50 and -78.13% deficit over its 52-week high. The stock witnessed -43.84% declines, -20.92% declines and -53.31% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found EYES’s volatility during a week at 14.02% and during a month it has been found around 10.34%.

Second Sight Medical Products, Inc. (EYES) Top Holders

Institutional investors currently hold around $5 million or 18.7% in EYES stock. Look at its top three institutional owners. Vanguard Group Inc owns $748 thousand in Second Sight Medical Products, Inc., which represents roughly 1.15% of the company’s market cap and approximately 14.96% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Fund Advisors, which owns 475,860 shares of the stock are valued at $738 thousand. The third largest holder is Blackrock Institutional Trust Company, N.A., which currently holds $582 thousand worth of this stock and that ownership represents nearly 0.89% of its market capitalization.

Second Sight Medical Products, Inc. 13F Filings

At the end of 12/31/2016 reporting period, 33 institutional holders increased their position in Second Sight Medical Products, Inc. (NASDAQ:EYES) by some 888,314 shares, 15 decreased positions by 213,238 and 19 held positions by 2,388,256. That puts total institutional holdings at 3,489,808 shares, according to SEC filings. The stock grabbed 13 new institutional investments totaling 550,613 shares while 5 institutional investors sold out their entire positions totaling 153,745 shares.

Second Sight Medical Products, Inc. (NASDAQ:EYES) Insider Trades

Multiple company employees have indulged in significant insider trading. Second Sight Medical Products, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chairman of Board Greenberg Robert J. has sold 1,950 shares of Second Sight Medical Products, Inc. (EYES) in trading session dated Dec. 01, 2016. These shares are worth $3,822 and were traded at $1.96 each. The SEC filing shows that Randolph Edward David performed a sale of 5,104 shares. The VP of Manufacturing disposed these shares by way of transaction on Jun. 03, 2016. The company’s shares were given away at $4.01 per share worth to an income of some $20,467 on account of Randolph Edward David.

Chairman of Board, Greenberg Robert J., sold 8,571 common shares of Second Sight Medical Products, Inc. (EYES) in the open market. In a transaction dated Jun. 02, 2016, the shares were put up for sale at an average price of $4.1, raking in a sum of $35,141. After this sale, 172,911 common shares of EYES are directly owned by the insider, with total stake valued at $228,243.

In the transaction dated Apr. 18, 2016, the great number of shares disposed came courtesy the Chairman of Board; Greenberg Robert J. disposed a total of 8,223 shares at an average price of $5.27, amounting to approximately $43,335. The insider now directly owns 172,911 shares worth $228,243.

Second Sight Medical Products, Inc. (EYES) Analyst Guide

Not many analysts have released their opinion on Second Sight Medical Products, Inc. (NASDAQ:EYES), with 1 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.

Previous article5 institutional investors are raising stakes in Jaguar Animal Health, Inc. (JAGX)
Next article11 hedge funds buy Profire Energy, Inc. (PFIE) for the first time